
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Allergy
Sec. Rhinology
Volume 6 - 2025 | doi: 10.3389/falgy.2025.1549332
This article is part of the Research Topic Innovation in the Management of Rhinologic Disorders View all 4 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The histopathologic study of nasal polyps establishes endotype features of chronic rhinosinusitis (CRS). A tissular eosinophil count greater than 10 per high power field (HPF) classifies this condition as type 2 inflammation. Blood and mucosal eosinophils are suggested as biomarkers of severity and control of CRS. Additionally, a tissular eosinophil count greater than 55 per HPF has been related to a high risk of recurrence in the Asian population. Our study aims to determine whether tissue eosinophil count is associated with the control, severity, and recurrence of chronic rhinosinusitis with nasal polyps (CRSwNP).Vizcarra-Melgar J et al.
Keywords: chronic rhinosinusitis with nasal polyps, Eosinophilic inflammation, Tissue eosinophilia, type 2 inflammation, Disease control, biomarkers, Recurrence
Received: 20 Dec 2024; Accepted: 31 Mar 2025.
Copyright: © 2025 Vizcarra-Melgar, Sánchez-Gómez, López-González, Moreno-Luna, González-García and Maza-Solano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Julissa Aida Vizcarra-Melgar, Hospital of Sant Joan Despí Moisès Broggi, Sant Joan Despi, 08970, Spain
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.